Pfizer: Raising awareness of the pneumococcus vaccine



Every year, pneumonia accounts for EUR 100 million in direct expenses for the Finnish healthcare system. However, there is a vaccine available that gives protection against the bacteria most often causing pneumonia, pneumococcus. The bacteria is especially active during the influenza season.

In autumn 2015, at the beginning of the influenza season, Pfizer launched a campaign aiming to increase awareness about pneumococcus. The pharmaceutical company utilised easily understood and effective infographics, fact sheets and a discussion session to raise public discourse about diseases caused by pneumococcus, the ensuing expenses for Finnish society and the savings made possible by the vaccine. In addition, the media work was supported by advertorials.

Interested?

Please contact Heli Suominen and Eva Niskanen for further information.

Heli Suominen
+358 40 356 2699
heli.suominen@miltton.fi

Eva Niskanen
+358 44 3671060
eva.niskanen@miltton.fi


Client: Pfizer